Nucor earnings beat by $0.08, revenue fell short of estimates
Investing.com -- CONMED Corporation (NYSE:CNMD) reported first-quarter 2025 results that beat analyst expectations, prompting the medical technology company to raise its full-year guidance. Shares of CONMED surged 4.8% following the announcement.
The company reported Q1 revenue of $321.3 million, surpassing the analyst consensus of $332.91 million. This represents a 2.9% increase YoY as reported and a 3.8% rise in constant currency. Adjusted earnings per share came in at $0.95, compared to $0.79 in the same quarter last year, but fell short of the $1.00 analyst estimate.
CONMED’s domestic revenue grew 4.2% YoY, while international revenue increased 1.2% as reported and 3.4% in constant currency. The company’s performance was driven by strengthened operations supporting key growth platforms.
"We had a good start to 2025, which positions us well to achieve our full-year guidance," said Patrick J. Beyer, CONMED’s President and CEO. "I am proud of our team’s dedication to strengthening our operations in order to better support our key growth platforms and drive long-term shareholder value."
CONMED raised its full-year 2025 outlook, now expecting revenue between $1.350 billion and $1.378 billion, up from its previous guidance of $1.344 billion to $1.372 billion. The company also increased its adjusted EPS forecast to $4.45-$4.60, compared to the prior range of $4.25-$4.40, surpassing the analyst consensus of $4.34.
The revised guidance reflects updated foreign currency expectations and first-quarter performance. However, it does not include the potential impact of recent tariff announcements, which CONMED estimates could negatively affect EPS by approximately $0.14 in the second half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.